Pacific Biosciences of California is a medical devices business based in the US. Pacific Biosciences of California shares (PACB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.13 – an increase of 3.67% over the previous week. Pacific Biosciences of California employs 575 staff and has a trailing 12-month revenue of around $154 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.13 |
|---|---|
| 52-week range | $1.06 - $2.72 |
| 50-day moving average | $1.28 |
| 200-day moving average | $1.67 |
| Wall St. target price | $2.14 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.59 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.13 from 2025-05-02
| 1 week (2025-04-25) | 3.67% |
|---|---|
| 1 month (2025-04-04) | -8.13% |
| 3 months (2025-02-05) | -31.10% |
| 6 months (2024-11-05) | -55.69% |
| 1 year (2024-05-03) | -38.25% |
|---|---|
| 2 years (2023-05-04) | -90.50% |
| 3 years (2022-05-04) | 7.29 |
| 5 years (2020-05-05) | 3.18 |
| Revenue TTM | $154 million |
|---|---|
| Gross profit TTM | $47.7 million |
| Return on assets TTM | -12.09% |
| Return on equity TTM | -51.3% |
| Profit margin | -201.18% |
| Book value | $1.72 |
| Market Capitalization | $339 million |
TTM: trailing 12 months
We're not expecting Pacific Biosciences of California to pay a dividend over the next 12 months.
Over the last 12 months, Pacific Biosciences of California's shares have ranged in value from as little as $1.06 up to $2.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacific Biosciences of California's is 2.033. This would suggest that Pacific Biosciences of California's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .